论文部分内容阅读
企业的并购行为是最正常不过的现象,自从我国的医药零售市场开放以来,业内的并购行为就没有停歇过,只不过之前的企业并购活动,规模偏小,也没有形成真正具有全国性影响力的大型企业。从2004年或2005年开始,未来几年,估计会出现与前五年不同的较大变化,无论是从规模还是到行业集中度,都会有较大的提升。”北京嘉事堂药业连锁总经理许帅如是说。2000年,国家鼓励药店从区域性企业向全国性企业发展,50家医药零售企业获得了跨省连锁经营资格,由此引发了中国医药流通行业史上的第一轮并购热潮。五年过去,潮起潮落,有大张旗鼓乘兴而来却铩羽而归者,也有稳扎稳打于不动声色间拓疆占土者……2004年,高盛4000万美金注资深圳海王星辰,在业内投下了一颗重磅炸弹,讶异者有之,羡慕者有之,在猜测着海王星辰的下一步动作之余,各企业也在殚精竭虑,思索着是否有适合自身的并购之路。
M & A behavior of enterprises is the most normal phenomenon. Since China’s pharmaceutical retail market was opened up, the M & A activity in the industry has not stopped. Only the previous M & A activity was too small in scale and did not form a real national influence Of large enterprises. From 2004 or 2005, it is estimated that major changes will occur in the next few years that are different from the previous five years, both in terms of scale and industry concentration. "Said Xu Shuai, general manager of Beijing Jiaotang Pharmaceutical Chain Co., Ltd. In 2000, the state encouraged pharmacies to develop from regional enterprises to national enterprises, and 50 pharmaceutical retailers obtained the qualification of inter-provincial chain operation. As a result, China Pharmaceutical Circulation industry in the history of the first round of mergers and acquisitions boom in the past five years, the ebb and flow of the ebb and flow, there is a lot of fanfare come to fruition, but also steadily play a pioneering role in the pioneer territory ... ... 2004, 40 million Goldman Sachs Neptune injection Shenzhen Neptune, in the industry dropped a blockbuster, surprised those who admire those, in speculation Neptune next move apart from the companies are also craving, pondering whether there is suitable for their own M & A road.